Lexicon’s Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the…